Orion Corporation: Managers’ transactions – Hilpi Rautelin

ORION CORPORATION
MANAGERS’ TRANSACTIONS
30 AUGUST 2023 at 15.30 EEST              
        

Orion Corporation: Managers’ transactions – Hilpi Rautelin

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Orion Oyj – Managers’ Transactions
____________________________________________
Person subject to the notification requirement
Name: Hilpi Rautelin
Position: Member of the Board/Deputy member
Issuer: Orion Oyj
LEI: 74370029VAHCXDR7B745
Notification type: INITIAL NOTIFICATION
Reference number: 37188/7/8

____________________________________________
Transaction date: 2023-08-28
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI0009014369
Nature of transaction: ACQUISITION

Transaction details
(1): Volume: 27 Unit price: 35.85 EUR
(2): Volume: 28 Unit price: 36 EUR
(3): Volume: 26 Unit price: 36.1 EUR
(4): Volume: 26 Unit price: 36.05 EUR
(5): Volume: 41 Unit price: 36.1 EUR
(6): Volume: 33 Unit price: 35.95 EUR
(7): Volume: 200 Unit price: 35.95 EUR
(8): Volume: 200 Unit price: 35.95 EUR
(9): Volume: 52 Unit price: 35.85 EUR
(10): Volume: 200 Unit price: 35.85 EUR
(11): Volume: 220 Unit price: 35.9 EUR
(12): Volume: 200 Unit price: 35.9 EUR

Aggregated transactions (12):
Volume: 1253 Volume weighted average price: 35.92219 EUR
____________________________________________
Transaction date: 2023-08-28
Venue: CEUD
Instrument type: SHARE
ISIN: FI0009014369
Nature of transaction: ACQUISITION

Transaction details
(1): Volume: 75 Unit price: 35.92 EUR

Aggregated transactions (1):
Volume: 75 Volume weighted average price: 35.92 EUR
____________________________________________
Transaction date: 2023-08-28
Venue: CEUX
Instrument type: SHARE
ISIN: FI0009014369
Nature of transaction: ACQUISITION

Transaction details
(1): Volume: 130 Unit price: 35.95 EUR
(2): Volume: 140 Unit price: 35.85 EUR

Aggregated transactions (2):
Volume: 270 Volume weighted average price: 35.89815 EUR
____________________________________________
Transaction date: 2023-08-28
Venue: TQEX
Instrument type: SHARE
ISIN: FI0009014369
Nature of transaction: ACQUISITION

Transaction details
(1): Volume: 40 Unit price: 35.95 EUR

Aggregated transactions (1):
Volume: 40 Volume weighted average price: 35.95 EUR
____________________________________________
Transaction date: 2023-08-29
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI0009014369
Nature of transaction: ACQUISITION

Transaction details
(1): Volume: 273 Unit price: 37 EUR
(2): Volume: 90 Unit price: 37 EUR
(3): Volume: 170 Unit price: 37 EUR
(4): Volume: 198 Unit price: 36.95 EUR
(5): Volume: 26 Unit price: 36.65 EUR
(6): Volume: 26 Unit price: 36.7 EUR
(7): Volume: 58 Unit price: 36.7 EUR
(8): Volume: 28 Unit price: 36.65 EUR
(9): Volume: 27 Unit price: 36.6 EUR
(10): Volume: 26 Unit price: 36.55 EUR
(11): Volume: 26 Unit price: 36.55 EUR
(12): Volume: 40 Unit price: 36.5 EUR
(13): Volume: 26 Unit price: 35.95 EUR

Aggregated transactions (13):
Volume: 1014 Volume weighted average price: 36.86637 EUR
____________________________________________
Transaction date: 2023-08-29
Venue: TQEM
Instrument type: SHARE
ISIN: FI0009014369
Nature of transaction: ACQUISITION

Transaction details
(1): Volume: 23 Unit price: 36.78 EUR
(2): Volume: 24 Unit price: 36.75 EUR
(3): Volume: 25 Unit price: 36.75 EUR
(4): Volume: 25 Unit price: 36.7 EUR

Aggregated transactions (4):
Volume: 97 Volume weighted average price: 36.74423 EUR
____________________________________________
Transaction date: 2023-08-29
Venue: CEUX
Instrument type: SHARE
ISIN: FI0009014369
Nature of transaction: ACQUISITION

Transaction details
(1): Volume: 181 Unit price: 36.95 EUR
(2): Volume: 30 Unit price: 36.95 EUR
(3): Volume: 40 Unit price: 36.95 EUR

Aggregated transactions (3):
Volume: 251 Volume weighted average price: 36.95 EUR

Orion Corporation

Liisa Hurme

President and CEO

    Olli Huotari

SVP, Corporate Functions

 

                                                

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion’s net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.

Staff

Recent Posts

Olympian Gabby Thomas Draws Crowd at Wellness Event with BetterWay(TM) Blood Testing at H-E-B SoCo

Guests had an opportunity to meet Gabby Thomas, win health-focused prizes, and learn simple ways…

5 hours ago

UOG (United One Group) Wins Three Prestigious Industry Awards at CES 2026

CES Official Spokesperson Highlights UOG Featured ProductsIntroducing the World's First Black Diamond Carbon & Nano…

14 hours ago

Best Ipamorelin vs Sermorelin: Growth Hormone Peptide Comparison 2026 — ReadyRx Prescription Telehealth Analysis

Independent research summary reviews mechanisms, regulatory considerations, and telehealth access pathways as consumers compare growth…

17 hours ago

GLP-1 Booster From Health Journey: 2026 Ingredient Analysis And Probiotic Metabolic Support Explained

Examining Akkermansia Muciniphila, Clostridium Butyricum, And The Gut Microbiome Research Behind This Probiotic GLP-1 Supplement…

17 hours ago

MEDVi GLP-1 Investigation: What Consumer Data Shows About Compounded Telehealth Weight Loss Programs

Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading…

17 hours ago